The Impact of Minimal Residual Disease
in Acute Lymphoblastic Leukemia
in Acute Lymphoblastic Leukemia
| Support for this program provided by: |
 |
Program Evaluation
Thank you for participating in the program. Your responses on this evaluation help us improve future programs. Please scroll down to complete the evaluation and submit your responses by clicking on the red button at the bottom of the page. Required questions are indicated with an asterick (*).
1. To what extent did this video provide information that will help you prepare for discussions with your healthcare team about MRD? *
2. As a result of viewing this presentation, please rate your agreement with the following statements about your knowledge of the topic:*
| Strongly Disagree | Disagree | Agree | Strongly Agree | |
|---|---|---|---|---|
| Current treatment options for patients living with ALL | ||||
| The impact of minimal residual disease (MRD) | ||||
| Clinical trials and emerging therapies for ALL treatment | ||||
| The importance of open communication with your healthcare team to promote a better quality of life |
3. What part of this video was most helpful to you?
5. Are you a cancer survivor? (LLS is using the term "survivor" to mean anyone diagnosed with cancer.) *
If not, what is your relationship to the survivor?
6. What was the diagnosis?
7. How long has it been since you (or the survivor) were diagnosed? *
8. What is your ZIP/Postal code? *
9. What is your age? *
10. What is your gender? *
11. Additional Comments:
If you have additional questions following this program, please contact an Information Specialist for accurate, up-to-date disease and treatment information, and for support with treatment and financial challenges you may be facing. (800) 955-4572 or infocenter@LLS.org.